ClinicalTrials.govcontrolled
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Op
ClinicalTrials.gov study NCT06042478. IPD Sharing: YES. Countries: 23. Publications: 0.
ShareScore
28/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 16
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4